



Vaccines and Global Health: The Week in Review
02 March 2024 :: Issue 740
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director

Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.*

Support this knowledge-sharing service: *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

Contents [click to move among sections]

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

:: [Think Tanks](#)

Milestones, Perspectives



[Africa CDC and UNICEF Expand Partnership to Strengthen Health Systems and Immunization of Children in Africa](#)

ADDIS ABABA/NEW YORK, 29 February 2024 - Today, the Africa Centres for Disease Control and Prevention (Africa CDC) and UNICEF announced an extended partnership dedicated to strengthening primary healthcare, supply chain management, pooled procurement and local manufacturing, and emergency response.

The collaboration builds on the 2022-2024 Partnership Framework Agreement between Africa CDC and UNICEF, which aims to achieve the goals outlined in the African Union Agenda 2063: The Africa We Want. **The partnership is expected to have a significant impact on public health in Africa by strengthening procurement and supply chain systems, with a particular focus on immunisation for children across the continent...**

During the past two years, UNICEF and Africa CDC have achieved significant milestones in **strengthening Africa CDC's institutional capacity and catalysing community health programmes, immunisation systems, emergency response, and supply chain enhancement**. Collaborative efforts secured the procurement of COVID-19 vaccine doses and essential cold chain equipment for routine immunisation. Joint high-level advocacy initiatives focused on immunisation, community health, and response to public health emergencies.

Africa imports 99% of its vaccines and 70 to 90% of its medicines and medical devices, which is a significant challenge. Africa CDC aims to achieve sustainable production and supply of essential health commodities through African manufacturers, considered Africa's second independence by Africa CDC. Africa CDC's goal is to work with African Union Member States and partners to actively advocate for and support the procurement of vaccines made in Africa and prioritise initiatives that strengthen local manufacturing.

Through the Partnership for Vaccine Manufacturing, Africa CDC aims to manufacture 60% of the continent's vaccine needs by 2040, paving the way toward robust and self-reliant health systems, ensuring that people can obtain and use health commodities when and where required.

The expanded partnership between Africa CDC and UNICEF signifies a concerted effort to address Africa's pressing health challenges. By prioritising immunisation, strengthening health systems, and promoting local production, both organisations are poised to make tangible and sustainable impacts on the health and well-being of children and communities across the continent while safeguarding Africa's health security.



TRIPS Extension

Briefing Note: Intellectual property

WTO [World Trade Organization] 13th MINISTERIAL CONFERENCE

TRIPS Decision extension

Following the landmark MC12 agreement on a waiver of certain requirements concerning compulsory licensing for COVID-19 vaccines, **WTO members had been discussing whether to extend the TRIPS Decision adopted at MC12 to COVID-19 diagnostics and therapeutics.**

Discussions did not deliver progress, with members largely reiterating their standing positions. Developing and least developed country (LDC) members contended that the concentration of manufacturing contributes to the inequitable rollout of COVID-19 diagnostics and therapeutics, while others questioned whether intellectual property is the cause of the access problem.

The first [report](#) adopted by members summarizes those discussions. The text recognizes the considerable efforts members have made to support a fact- and evidence-based discussion on paragraph 8 of the MC12 Decision on the TRIPS Agreement regarding its possible extension to cover COVID-19 diagnostics and therapeutics. It also acknowledges that despite these efforts, **consensus could not be reached on the extension of the Decision.**

COVID-19 pandemic response and preparedness for future pandemics

The second [report](#) notes that **the TRIPS Council will continue its work** as directed by the Ministerial Declaration from MC12 **to review and build on all the lessons learned and the challenges experienced during the COVID-19 pandemic**, and to build effective solutions in case of future pandemics, in an expeditious manner.

The role of intellectual property (IP), and more specifically voluntary licensing, technology transfer, the operation of the Medicines Patent Pool (MPP), geographical limitations of licences and the operation of Article 31(f) of the TRIPS Agreement were noted as areas of interest to members in that context.

Both reports were the result of the intense consultations held by the Council Chair, Ambassador Pimchanok Pitfield of Thailand, with a number of delegations and group coordinators over the past few months. She thanked members for their flexibility in reaching consensus and encouraged them to now focus on the preparation of the MC13 outcome document with respect to IP issues.

.....

IFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi

Statement 1 Mar 2024

At the end of the 13th WTO Ministerial Conference in Abu Dhabi, Thomas Cueni, IFPMA Director-General said:

“After much prolonged discussion, WTO Members at the Abu Dhabi Ministerial Conference did not agree to extend the TRIPS waiver for COVID-19 vaccines to cover therapeutics and diagnostics.

“Intellectual Property is a critical enabler for the development of medicines and vaccines. It has also given companies the confidence to engage and has enabled more than 177 voluntary collaborations, including technology transfer initiatives on COVID-19 therapeutics alone.

“We encourage WTO Members to now focus on a comprehensive trade and health agenda, such as removing export restrictions, promoting trade facilitation and regulatory convergence. We look forward to continued engagement on these important issues.”

.....



One million vaccine doses administered to children living in humanitarian settings in the Horn of Africa

- **Gavi, working with the International Rescue Committee (IRC)**, has administered one million doses of life-saving vaccines to children living in fragile and conflict-affected areas across Ethiopia, Somalia, Sudan and South Sudan.
- The partnership with the IRC is part of **Gavi’s innovative Zero-Dose Immunization Programme (ZIP)**, which is aimed at reaching children who have previously never been vaccinated.
- Thabani Maphosa, Managing Director of Country Programmes Delivery at Gavi: “Children living in hard-to-reach communities now have a fighting chance for a better future.”
- Shiferaw Demissie, Project Director for Gavi REACH at the IRC: “Through innovative strategies and strategic partnerships, the IRC-led Gavi REACH consortium is bridging the equity gap in immunisation.”

Geneva, 22 February 2024 – One million doses of life-saving vaccines have been administered to children living across Ethiopia, Somalia, Sudan and South Sudan, thanks to the Zero-Dose Immunization Programme (ZIP). Funded by Gavi, the Vaccine Alliance and led by the International Rescue Committee (IRC) in the Horn of Africa, **ZIP is responding to the humanitarian challenge of identifying and vaccinating zero-dose children living in fragile settings that are beyond the reach of government health services. More than half of the 2.71 million children in the region aged under five years have never received a vaccine in their lives.**

“Children living in hard-to-reach communities now have a fighting chance for a better future,” said Thabani Maphosa, Managing Director of Country Programmes Delivery at Gavi. “But our work is not done: millions of children who are already vulnerable due to conflict, natural disasters and other challenges continue to be under-served by traditional health systems, and systemically miss out on essential vaccines. Innovative partnerships such as this one with the IRC are essential if we are to ensure no child is left behind.”

In partnership with Flowminder, ThinkPlace and a broad coalition of local civil society organisations, the IRC is building on its humanitarian expertise to successfully deliver results through ZIP. In Ethiopia, Somalia, Sudan and South Sudan, humanitarian negotiators are working closely with vaccination teams to access communities living in conflict-ridden areas and vaccinate children who are the hardest to reach. According to the latest data, at the beginning of the programme only 16% of the total targeted areas in the region were accessible. Through successful negotiation, 77% can now be accessed to deliver immunisation. Partners are also integrating health programmes to provide services, including nutrition, and vaccines in one place...

In 2021, there were more than 4.5 million zero-dose children living across the 11 target ZIP countries. **Recognising that new methods were necessary to address low immunisation coverage and equity gaps, Gavi launched ZIP, dedicating up to US\$ 100 million and leveraging new partnerships to identify and reach zero-dose children living in fragile and conflict settings** across Africa. The IRC and World Vision were selected to lead the initiative in the Horn of Africa and the Sahel regions respectively, due to their extensive experience in conflict areas and strong footprint in remote areas.



A Framework for Tomorrow’s Pathogen Research – Final Report

Executive Summary

[Excerpt]

...Recognizing the need for a focused conversation on the risks and benefits of a subset of research that could plausibly source a large outbreak, or even a pandemic, the **Bulletin convened an independent and international panel of experts in biosafety, biosecurity, epidemiology, ethics, genetic engineering, virology, and other areas: the Task Force on Research with Pandemic Risks.**

The **scope of the research** examined by the Task Force included

- (1) research on pathogens known to be capable of causing a pandemic that under current conditions (e.g., low population immunity) could result in extensive spread beyond the current infection burden;
- (2) manipulation of pathogens that are not currently thought capable of pandemic spread in ways that can be anticipated to increase their capacity to cause a pandemic (e.g., by increasing virulence or transmissibility); and
- (3) research on pathogens with unknown characteristics.

The Task Force's report discusses the potential benefits of virology research and outlines how advances in science and technology may increase certain benefits. It then focuses on some of the potential risks of virology research, including biosafety and biosecurity, and outlines how advances in science and technology may increase some of these risks. **The Task Force also examined ethical obligations to make research with pandemic risks more safe, secure, and responsible**, suggesting actionable and sustainable strategies to effectively maximize the potential benefits and mitigate the foreseeable potential harms of research with known or potential pandemic pathogens, while attending to issues of equity and proportionality.

The report argues for empirical studies on biosafety and biosecurity to make research with pandemic risks more safe, secure, and responsible. It also reviews the contemporary governance space for research with known or potential pandemic pathogens and argues that effective legislation, regulations, policies, and guidelines specifically regulating such research will strengthen the scientific enterprise and should be put in place and implemented without delay. It discusses challenges in building and sustaining trust in science in general and research with pandemic risks more specifically. Finally, the Task Force has issued several recommendations.

Key recommendations include:

- Research with pandemic risks should have **high-probability benefits for public health.**
- Where feasible, research questions about pathogens with pandemic risk should be addressed **using surrogate systems, or by taking advantage of loss-of-function experiments on current human viruses.**
- International protocols should be established for research on pandemic risk pathogens. Those protocols should include methods for both sample collection and laboratory work.
- Research on pandemic risk pathogens should be **monitored locally, nationally and internationally.** Funds should be allocated to optimize biorisk management strategies.

- Scientific journals and their editors should enforce timely data-sharing and research integrity for the manuscripts they publish.

At present, occupational health and safety governance generally adequately weighs the direct biosafety risks to the researcher in the laboratory, but there is a small subset of research on known or potential pandemic pathogens for which biosafety risks go beyond the laboratory and affect the health of significantly larger groups of humans or other animals. Indeed, if a virus has true pandemic potential, the entire world can be affected by an accident.

Navigating research with pandemic risks warrants additional precautions. The overarching aim of the Task Force on Research with Pandemic Risks is to guide the development of a safe, secure, and responsible research environment for researchers, and in so doing, to earn public trust.



WHO - [Strategic Advisory Group of Experts on Immunization \(SAGE\) - March 2024](#)

11 – 14 March 2024 Geneva

[Draft agenda](#)

- Global and regional reports – Session 1
- IA2030 deep dive – Session 2
- Polio – Session 3
- Hepatitis E – Session 4
- COVID-19 – Session 5
- Mpox – Session 6
- Immune correlates – Session 7
- RSV – Session 8



Polio – PHEIC

[Polio this week as of 28 Feb 2024 - GPEI](#)

Headlines

:: To mark the International Women’s Day on the 8th of March, you are invited to attend a webinar about the powerful impact of women in the global effort to eradicate polio. During the webinar, women working on the frontlines in Afghanistan, the Democratic Republic of the Congo, Nigeria and Pakistan will share the experiences and challenges they face in the fight against polio. More information and registration details are [available here](#).

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: one WPV1-positive environmental sample
- Algeria: one cVDPV2-positive environmental sample
- Liberia: one cVDPV2-positive environmental sample
- Nigeria: one cVDPV2 case and one positive environmental sample



[Contents \[click to move among sections\]](#)

:: [Milestones, Perspectives](#)
:: [WHO](#)
:: [Organization Announcements](#)
:: [Journal Watch](#)
:: [Pre-Print Servers](#)

.....
.....

WHO & Regional Offices [to 02 Mar 2024]

<https://www.who.int/news>

Selected News/Announcements/Statements

29 February 2024 Departmental news

[WHO launches Pharmaceutical Quality Assurance guidelines, 10th edition](#)

29 February 2024 News release

[Leaders call for scale-up in implementing One Health approach](#)

29 February 2024 Departmental news

[Message from the Director - Outlook for 2024](#)

29 February 2024 Departmental news

[WHO launches a Repository of systematic reviews on interventions in environment, climate change and health](#)

27 February 2024 News release

[Inclusion of noncommunicable disease care in response to humanitarian emergencies will help save more lives](#)

.....

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

[Africa immunization advisory group urges single-dose HPV vaccine adoption to advance vaccination efforts](#)

01 March 2024

Brazzaville –Cervical cancer poses a significant burden in sub-Saharan Africa, with 120,000 cases annually out of the global total of 690,000, further exacerbated by the HIV epidemic.

In an effort to accelerate progress against cervical cancer, the WHO Africa Regional Immunization Technical Advisory Group (RITAG) during a meeting held 7 – 9 November 2023 has urged countries to adopt a single-dose schedule for the human papillomavirus vaccine (HPV) in Africa, in line with the World Health Organization's (WHO) recommendations in 2022. Implementation of this recommendation represents a significant step forward in the region's fight against cervical cancer.

Currently, 27 African nations have incorporated the HPV vaccine into their routine immunization programmes, with a primary focus on girls aged 9-14...

WHO Region of the Americas PAHO

No new digest content identified.

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

:: 27 February 2024 News release

[Türkiye-Syria: Protecting the overlooked and vulnerable in the wake of the earthquakes](#)

WHO Eastern Mediterranean Region EMRO

No new digest content identified.

WHO Western Pacific Region

:: 1 March 2024 News release

[Western Pacific countries at risk of measles outbreaks due to immunization and surveillance...](#)

.....

WHO - Emergency situation reports

No new digest content identified.

.....

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

[27 February 2024 | Nipah virus infection - Bangladesh](#)

.....

Weekly Epidemiological Record

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 99, No. 09, pp. 95–104 1 March 2024

<https://iris.who.int/bitstream/handle/10665/376150/WER9909-eng-fre.pdf>

:: Report of the meeting of the WHO Global Advisory Committee on Vaccine Safety and the WHO Advisory Committee on Safety of Medicinal, 13–15 November 2023

.....

New WHO Publications

<https://www.who.int/publications/i>

Selected

1 March 2024

[Infection prevention and control measures when caring for patients with suspected or confirmed respiratory...](#)

1 March 2024

[Introducing a framework for implementing triple elimination of mother-to-child transmission of HIV, syphilis...](#)

29 February 2024

[HIV drug resistance – brief report 2024](#)

29 February 2024

[Infection prevention and control and water, sanitation and hygiene measures for diphtheria in health-care...](#)

26 February 2024

[Citizen engagement in evidence-informed policy-making: a guide to mini-publics](#)

.....
.....

USA – HHS, FDA, CDC

HHS

News

[Readout of HHS Secretary Xavier Becerra’s Meeting with Director-General of the World Health Organization](#)

February 28, 2024 *News Release*

On February 22nd, U.S. Secretary of Health and Human Services (HHS) Xavier Becerra spoke with Director-General of the World Health Organization (WHO) Dr. Tedros Adhanom Ghebreyesus regarding the current pandemic accord negotiations. During the call, the Secretary stressed the importance of establishing a global agreement that would make America and the world better prepared in the future, and they agreed to continue working together to find common ground.

FDA

Press Announcements

[FDA Roundup: March 1, 2024](#)

...Today, the FDA reminded consumers that measles is not a harmless childhood disease in the Vaccination Is the Best Protection Against Measles Consumer Update. Measles is dangerous and can be life-threatening. Our most effective public health measure against measles is prevention with a measles vaccine. Vaccines approved by the FDA for the prevention of measles are proven both safe and effective. Most people who get the recommended two doses of a vaccine to prevent measles will have lifelong protection and will never get sick with measles, even if they’re exposed to the virus.

FDA VRBPAC

Advisory Committee Calendar

[Vaccines and Related Biological Products Advisory Committee March 5, 2024 Meeting Announcement](#) - 03/05/2024

CDC/ACIP [U.S.] [to 02 Mar 2024]

<http://www.cdc.gov/media/index.html>

Latest News Releases

[CDC updates and simplifies respiratory virus recommendations](#)

March 1, 2024 CDC released today updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19.

[Older Adults Now Able to Receive Additional Dose of Updated COVID-19 Vaccine](#)

February 28, 2024 CDC Director Mandy Cohen endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for adults ages 65 years and older to receive an additional updated 2023-2024 COVID-19 vaccine dose.

ACIP Meetings

Next ACIP Meeting

No meetings listed.

MMWR Weekly

<https://www.cdc.gov/mmwr/index2023.html>

February 29, 2024 / No. 8

[PDF of this issue](#)

- [Progress Toward Rubella and Congenital Rubella Syndrome Elimination — Worldwide, 2012–2022](#)
- [Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness — United States](#)
- [Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza — California, October 2023–January 2024](#)
- [Interim Effectiveness of Updated 2023–2024 \(Monovalent XBB.1.5\) COVID-19 Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalization Among Immunocompetent Adults Aged ≥18 Years — VISION and IVY Networks, September 2023–January 2024](#)

.....
.....

Europe

European Medicines Agency [EMA]

<https://www.ema.europa.eu/en/news>

News & Press Releases

No new digest content identified.

.....

European Centre for Disease Prevention and Control

<https://www.ecdc.europa.eu/en>

News/Updates/Reports/Publications [Selected]

No new digest content identified.

.....
.....

Africa CDC [to 02 Mar 2024]

<http://www.africacdc.org/>

Press Releases, Statements [Selected]

Press Releases

[Africa CDC and UNICEF Expand Partnership to Strengthen Health Systems and Immunization of Children in Africa](#)

29 February 2024

.....
.....

China CDC

<http://www.chinacdc.cn/en/>

National Health Commission of the People's Republic of China [to 02 Mar 2024]

<http://en.nhc.gov.cn/>

News

No new digest content identified.

National Medical Products Administration – PRC [to 02 Mar 2024]

<http://english.nmpa.gov.cn/>

News

No new digest content identified.

China CDC

Weekly Reports: Current Volume (6)

2024-03-01 / No. 9

[View PDF of this issue](#)

No new digest content identified.

.....
.....

Contents [click to move among sections]

:: [*Milestones, Perspectives*](#)

:: [*WHO*](#)

:: [*Organization Announcements*](#)

:: [*Journal Watch*](#)

:: [*Pre-Print Servers*](#)

.....
.....

Organization Announcements

Paul G. Allen Frontiers Group [to 02 Mar 2024]

<https://alleninstitute.org/news-press/>

News

No new digest content identified.

BMGF - Gates Foundation [to 02 Mar 2024]

<https://www.gatesfoundation.org/ideas/media-center>

Press Releases and Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 02 Mar 2024]

<https://www.gatesmri.org/news>

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people

News: Articles and Publications

No new digest content identified.

CARB-X [to 02 Mar 2024]

<https://carb-x.org/>

News

02.29.2024 |

[CARB-X funds GlyProVac to develop a novel vaccine to prevent sepsis in newborns](#)

CARB-X is awarding GlyProVac US\$467k to develop a maternal vaccine that targets Escherichia coli, a bacterial species that causes a large portion of neonatal sepsis infections.

02.27.2024 |

[CARB-X funds LimmaTech Biologics AG to develop a vaccine that prevents gonorrhea infections](#)

CARB-X is awarding US\$2.2 million to LimmaTech Biologics AG to advance the development of its novel vaccine candidate targeted to prevent Neisseria gonorrhoeae infections.

CEPI – Coalition for Epidemic Preparedness Innovations [to 02 Mar 2024]

<http://cepi.net/>

Latest News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 02 Mar 2024]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 02 Mar 2024]

<https://www.darpa.mil/news>

News

No new digest content identified.

Duke Global Health Innovation Center [to 02 Mar 2024]

<https://dukeghic.org/>

News

No new digest content identified.

EDCTP [to 02 Mar 2024]

<http://www.edctp.org/>

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

News

No new digest content identified.

Emory Vaccine Center [to 02 Mar 2024]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

European Vaccine Initiative [to 02 Mar 2024]

<http://www.euvaccine.eu/>

Latest News, Events

[TBVI announces the appointment of its new Executive Director](#)

The TBVI Governance Board is pleased to announce the appointment of Dr. Ole F. Olesen as their new Executive Director.

Evidence Aid [to 02 Mar 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

<http://www.evidenceaid.org/>

Resources [Selected]

[Impact of the COVID-19 pandemic on sedentary time in children and adults](#)

Added March 2, 2024

[School closures and mental health among children and adolescents during COVID-19](#)

Added March 1, 2024

[Interventions to improve childhood immunisation coverage in low- and middle-income countries](#)

Added February 24, 2024

Fondation Merieux [to 02 Mar 2024]

<http://www.fondation-merieux.org/>

News, Events

No new digest content identified.

Gavi [to 02 Mar 2024]

<https://www.gavi.org/>

News Releases

28 February 2024

[Lao PDR receives over 650,000 doses of measles and rubella vaccine with support from Gavi](#)

The donation by Gavi, targeting over 600,000 children aged under five, comes at a time when measles cases are on the rise globally due to low vaccination rates among children from hard-to-reach communities who face multiple deprivations and vulnerabilities.

27 February 2024

[PAHO and Gavi collaborate to inform countries about New Vaccine Introductions](#)

27 February 2024

[Nearly US\\$ 20 million made available to improve health care services through agreements between Government of Pakistan, Gavi and UNICEF](#)

GE2P2 Global Foundation [to 02 Mar 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – March 2024](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 14 February 2024 – Issue 13](#)

GHIT Fund [to 02 Mar 2024]

<https://www.ghitfund.org/newsroom/press>

Press Releases

No new digest content identified.

Global Fund [to 02 Mar 2024].

<https://www.theglobalfund.org/en/news/>

News & Stories

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 02 Mar 2024]

<https://www.glopid-r.org/news/>

News

No new digest content identified.

Hilleman Laboratories [to 02 Mar 2024]

<http://www.hilleman-labs.org/>

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 02 Mar 2024]

<https://www.hhmi.org/news>

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 02 Mar 2024]

<http://www.humanvaccinesproject.org/>

News

No new digest content identified.

IAVI [to 02 Mar 2024]

<https://www.iavi.org/>

News, Features

[IAVI statement on mRNA HIV vaccine candidate trials](#)

March 2, 2024

Response to Science news article

IAVI is currently in the process of finalizing and submitting a manuscript for publication of the results of the [IAVI G002](#) clinical trial. The forthcoming publication will describe in detail both the immune responses and the safety outcomes observed in the trial.

On March 1, Science published a news article about skin events observed in recent HIV vaccine clinical trials evaluating a "[germline-targeting](#)" approach to HIV vaccine development, including IAVI G002. IAVI G002 is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can activate specific naive B-cells and guide their early maturation toward broadly neutralizing antibody (bnAb) production...

Press Releases

[**IAVI and WomenLift Health announce partnership to promote women's leadership in global health**](#)

February 27, 2024

Memorandum of understanding targets gender equity, mentorship, and training to expand the power and influence of talented [women in science](#).

INSERM [to 02 Mar 2024]

<https://www.inserm.fr/en/home/>

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

<http://www.icmra.info/drupal/en/news>

Selected Statements, Press Releases, Research

No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use [to 02 Mar 2024]

<https://www.ich.org/page/press-releases>

News/Pubs/Press Releases [Selective]

No new digest content identified.

ICRC [to 02 Mar 2024]

<https://www.icrc.org/en/whats-new>

What's New [Selected]

[**Update of customary IHL database – February 2024**](#)

In February 2024, we updated the customary IHL database to include additional practice from Brazil and the Philippines.

27-02-2024 | Article

IFFIm

<http://www.iffim.org/>

Press Releases/Announcements

No new digest content identified.

IFRC [to 02 Mar 2024]

<http://media.ifrc.org/ifrc/news/press-releases/>

Press Releases [Selected]

No new digest content identified.

Institut Pasteur [to 02 Mar 2024]

<https://www.pasteur.fr/en/press-area>

Press Documents

No new digest content identified.

ISC / International Science Council [to 02 Mar 2024]

<https://council.science/current/>

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

Blogs

[Support for the integrity of Argentina's science system](#)

In an letter to the network of authorities of research institutions in Argentina (RAICyT), the ISC expresses its concern regarding the future of Argentina's science system. The ISC offers its assistance in working with local and regional communities to develop a robust science sector which contributes to Argentina's social, environmental and economic success...

International Union of Immunological Societies (IUIS)

<https://iuis.org/>

News/Events [Selected]

No new digest content identified.

IVAC [to 02 Mar 2024]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

Updates; Events

No new digest content identified.

IVI [to 02 Mar 2024]

<http://www.ivi.int/>

IVI News & Announcements

[IVI opens a new Country and Project Office in Kenya that will lead the AVEC Africa project, working with partners and stakeholders on end-to-end vaccine R&D to ensure sustainable vaccine manufacturing in Africa](#)

February 28, 2024, SEOUL, Republic of Korea – The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, announced today that it will open a Country and Project Office in Kenya dedicated to the operations of its Advancing Vaccine End-to-End Capabilities (AVEC) initiative in Africa as well as other collaborations with Kenyan partners such as Kenya BioVax Institute across vaccine research, development, and training.

AVEC Africa is an accelerator of the regional vaccine ecosystem through the implementation of end-to-end research and development projects in Africa. The grassroots model activates public-private partnerships to drive projects based on local and regional need while promoting hands-on training and experience to develop the products, people, policy, and infrastructure needed to power an integrated and sustainable vaccine ecosystem in Africa. The IVI Board of Trustees (BOT) approved the decision to pursue AVEC Africa as part of a regional strategy and to establish a Country and Project Office in Kenya to oversee the initiative during an Executive Committee meeting this month...

[IVI to open Africa Regional Office in Rwanda](#)

February 27, 2024

Johns Hopkins Center for Health Security [to 02 Mar 2024]

<https://centerforhealthsecurity.org/newsroom>

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 02 Mar 2024]

<http://www.msf.org/>

Latest [Selected Announcements]

Zambia

[MSF responds to a surge in cholera in Zambia amid regional outbreaks](#)

Project Update 28 Feb 2024

Belarus

[Two years of response to the acute humanitarian crisis at EU's eastern borders](#)

Project Update 28 Feb 2024

Gaza-Israel war

[Attacks on humanitarian workers in Gaza make vital assistance nearly impossible](#)

Project Update 27 Feb 2024

Cholera

[Responding to cholera is a multipronged approach](#)

Interview 23 Feb 2024

National Academy of Medicine - USA [to 02 Mar 2024]

<https://nam.edu/programs/>

News [Selected]

No new digest content identified.

National Academy of Sciences - USA [to 02 Mar 2024]

<https://www.nationalacademies.org/newsroom?>

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 02 Mar 2024]

<https://www.hhs.gov/vaccines/about/index.html>

Upcoming Meetings/Latest Updates

No new digest content identified.

NIH [to 02 Mar 2024]

<http://www.nih.gov/>

News Releases

[New antibodies target “dark side” of influenza virus protein](#)

March 1, 2024 — NIH researchers explore hidden, vulnerable region of influenza neuraminidase.

PATH [to 02 Mar 2024]

<https://www.path.org/media-center/>

Newsroom

No new digest content identified.

Sabin Vaccine Institute [to 02 Mar 2024]

<https://www.sabin.org/press/>

Latest News & Press Releases

No new digest content identified.

UNAIDS [to 02 Mar 2024]

<http://www.unaids.org/en>

Selected Press Releases/Reports/Statements

Press statement

[On the 10th anniversary of Zero Discrimination Day UNAIDS calls for the protection of human rights as a path to protecting health for all](#)

GENEVA, 27 February 2024—Zero Discrimination Day was established by UNAIDS ten years ago to advance equality and fairness for everyone regardless of gender, age, sexuality, ethnicity or HIV status. However, progress is in peril...

UNICEF [to 02 Mar 2024]

<https://www.unicef.org/media/press-releases>

Latest press releases, news notes and statements

Press release 29 February 2024

[Africa CDC and UNICEF Expand Partnership to Strengthen Health Systems and Immunization of Children in Africa](#)

ADDIS ABABA/NEW YORK, 29 February 2024 - Today, the Africa Centres for Disease Control and Prevention (Africa CDC) and UNICEF announced an extended partnership dedicated to strengthening primary healthcare, supply chain management, pooled procurement and local manufacturing, and emergency response.

Unitaid [to 02 Mar 2024]

<https://unitaid.org/>

Featured News

No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 02 Mar 2024]

<https://vaccineequitycooperative.org/news/>

News

No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 02 Mar 2024]

<https://www.vaccineacceptance.org/>

Announcements, Blog

No new digest content identified.

Vaccine Confidence Project [to 02 Mar 2024]

<http://www.vaccineconfidence.org/>

News, Research and Reports

No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 02 Mar 2024]

<http://www.chop.edu/centers-programs/vaccine-education-center>

News

[Vaccine Update for Providers](#)

March 2024

Announcements: New addition, plus approaching deadline and new resources

April "Current Issues in Vaccines" webinar

Registration is now open for the next "Current Issues in Vaccines" webinar. Scheduled for April 3, 2024, at noon ET, Dr. Offit will discuss:

Covid-19 Vaccine Myths: And the Hits Just Keep on Comin’

[Find out more or register today.](#)

Wellcome Trust [to 02 Mar 2024]

<https://wellcome.org/>

News. Opinion, Reports

No new digest content identified.

The Wistar Institute [to 02 Mar 2024]

<https://www.wistar.org/news/press-releases>

Press Releases

[The Wistar Institute Appoints Max Berger to its Board of Trustees](#)

PHILADELPHIA — (Feb 27, 2024) — The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious disease, is pleased to welcome Max Berger to its Board of Trustees...

World Bank [to 02 Mar 2024]

<http://www.worldbank.org/en/news/all>

All News [Selected]

[Malaria](#)

Date: February 26, 2024 Type: Brief

Malaria control is an important part of the World Bank's health portfolio. The Bank's Health, Nutrition and Population portfolio is valued at \$34 billion dollars (as of 2023) and focuses on strengthening health systems, with focus on building strong primary health care systems that have linkages with community health interventions.

...Approach

The World Bank treats financing for malaria control as an integral part of financing for essential health services. The Bank works with countries to ensure that essential health interventions (including malaria) are adequately planned, costed and budgeted for in national health sector plans in a sustainable manner.

The Bank uses a two-pronged approach to support malaria control efforts: First, scaling up effective interventions and second, strengthening systems issues such as supply chain, human resources, and monitoring and evaluation. Strengthening health systems and ensuring that countries perform essential public health functions such as surveillance, will be critical for countries to sustain gains and continue toward elimination of malaria...

WFPHA: World Federation of Public Health Associations [to 02 Mar 2024]

<https://www.wfpha.org/>

Blog

[WFPHA joins call for WHO action on Climate Change Obligations before International Court](#)

Feb 28, 2024

WFPHA has joined forces with other international organizations to sign a letter addressed to Dr. Tedros, encouraging the continuation of WHO's leadership role...

[World Medical Association \[WMA\]](#) [to 02 Mar 2024]

<https://www.wma.net/news-press/press-releases/>

Press Releases

No new digest content identified.

World Organisation for Animal Health [to 02 Mar 2024]

<https://www.oie.int/en/>

Press Releases, Statements

No new digest content identified.

.....

ARM [Alliance for Regenerative Medicine] [to 02 Mar 2024]

<https://alliancerm.org/press-releases/>

Selected Press Releases

No new digest content identified.

BIO [to 02 Mar 2024]

<https://www.bio.org/press-releases>

Press Releases

[WTO 13th Ministerial Conference outcome "positive" for IP, future of biotech industry](#)

March 1, 2024

Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: "We are encouraged that WTO Members did not agree to extend an intellectual property..."

DCVMN – Developing Country Vaccine Manufacturers Network [to 02 Mar 2024]

<http://www.dcvmn.org/>

News; Upcoming events

No new digest content identified.

ICBA – International Council of Biotechnology Associations [to 02 Mar 2024]

<https://internationalbiotech.org/news/>

News

No new digest content identified.

IFPMA [to 02 Mar 2024]

<https://ifpma.org/>

News

Statement 1 Mar 2024

[IFPMA Statement at the closing of the WTO Ministerial Conference in Abu Dhabi](#)

At the end of the 13th WTO Ministerial Conference in Abu Dhabi, Thomas Cueni, IFPMA Director-General said:

"After much prolonged discussion, WTO Members at the Abu Dhabi Ministerial Conference did not agree to extend the TRIPS waiver for COVID-19 vaccines to cover therapeutics and diagnostics.

"Intellectual Property is a critical enabler for the development of medicines and vaccines. It has also given companies the confidence to engage and has enabled more than 177 voluntary collaborations, including technology transfer initiatives on COVID-19 therapeutics alone.

"We encourage WTO Members to now focus on a comprehensive trade and health agenda, such as removing export restrictions, promoting trade facilitation and regulatory convergence. We look forward to continued engagement on these important issues."

International Alliance of Patients' Organizations – IAPO [to 02 Mar 2024]

<https://www.iapo.org.uk/news>

Press and media [Selected]

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

<https://www.igbamedicines.org/>

News

No new digest announcements identified.

PhRMA [to 02 Mar 2024]

<http://www.phrma.org/>

Press Releases

[Equitable Breakthroughs in Medicine Development Reaches Next Phase Driving Diversity in Clinical Trials in Georgia, South Carolina, Tennessee, and Texas](#)

PhRMA

WASHINGTON, D.C. (February 26, 2024) – Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, and Vanderbilt University Medical Center, is a partnership bringing clinical trial sites closer to the community to further equity and access for diverse populations. Today, EQBMED announced the selection of the first four Learning Phase sites, moving the needle closer to a scalable and sustainable clinical trial model in historically underserved communities. The partnerships include:

- Morehouse School of Medicine and Grady Health System in Atlanta, Georgia;
- Yale School of Medicine and Medical University of South Carolina in Florence, South Carolina;
- Research Centers in Minority Institutions Coordinating Center (RCMI) at Morehouse School of Medicine, Texas Southern University in Houston and University of Texas Medical Branch in Galveston, Texas; and
- Vanderbilt University Medical Center and Meharry Medical College in Nashville, Tennessee.

The selection of these sites is part of EQBMED's plan to identify an initial 10 community-facing clinical trial sites in historically underrepresented communities of color across the country...



Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca

Press Releases - No new digest announcements identified.

Bharat Biotech

Press Releases - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias - No new digest announcements identified

Biological E

News

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

- Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENG A Per Year, Accelerating Takeda's Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest
 - Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to Help Protect the Most Vulnerable Populations
 - Dengue Incidence Continues to Increase and Poses a Growing Threat to Public Health Worldwide
- Feb 27, 2024

BioNTech

Press Releases - No new digest announcements identified

Boehringer

Press Releases - No new digest announcements identified.

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals - China

News - No new digest announcements identified.

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified

<https://sputnikvaccine.com/> - No new digest announcements identified

GSK

Press releases for media

Press releases

29 February 2024

[GSK announces Dr Jeannie Lee to join the Board as Non-Executive Director](#)

GSK plc (LSE/NYSE: GSK) has today announced that Dr Jeannie Lee has been appointed to the Board of the Company as a Non-Executive Director.

28 February 2024

[ViiV Healthcare to present data for its next generation of ultra long-acting treatments for HIV](#)

Key abstracts to be presented at CROI 2024 by ViiV Healthcare and its study partners.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

Press Releases - No new digest announcements identified

Merck

News releases - No new digest announcements identified

Moderna

Press Releases - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

News - No new digest announcements identified.

Novavax

Press Releases

Feb 28, 2024

Statement COVID-19

[Novavax's Protein-based Non-mRNA COVID-19 Vaccine Available Now as Additional Dose for Individuals Aged 65 and Older Following U.S. CDC Advisory Committee Recommendation](#)

Pfizer

[Recent Press Releases](#)

02.29.2024

[Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults](#)

- ABRYSVO, a bivalent vaccine, maintained consistently high protective efficacy for both RSV A and RSV B disease through two seasons after a single dose.
- ABRYSVO efficacy was 77.8% against RSV lower respiratory tract disease with three or more symptoms in a second full RSV season in adults 60 years of age or older.

R-Pharm

<https://rpharm-us.com/index.php>

[No news or media page identified]

Sanofi Pasteur

[Press Releases](#) - No new digest announcements identified

Serum Institute of India

[NEWS & ANNOUNCEMENTS](#) - No new digest announcements identified

Sinopharm/WIBPBIBP

[News](#) - No new digest announcements identified [English translation function not operating]

Sinovac

[Press Releases](#) - No new digest announcements identified

SK Biosciences

[Press Releases](#) - No new digest announcements identified

Takeda

[Newsroom](#)

[Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas](#)

February 26, 2024

- Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENG A Per Year, Accelerating Takeda's Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest
- Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to Help Protect the Most Vulnerable Populations
- Dengue Incidence Continues to Increase and Poses a Growing Threat to Public Health Worldwide

Valneva

[Press Releases](#)

February 29, 2024

[U.S. CDC Advisory Committee \(ACIP\) Recommends Use of Valneva's Single-Dose Chikungunya Vaccine IXCHIQ®](#)

- Recommendation for use in travelers and laboratory workers follows U.S. Food and Drug Administration (FDA) approval in November 2023[1]

- IXCHIQ® is the first and only vaccine approved to address this unmet medical need in adults aged 18 years and older who are at increased risk of exposure to the chikungunya virus

Vector State Research Centre of Virology and Biotechnology

Home - Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

Website [No News/Announcements page identified]



Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers



Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

AMA Journal of Ethics

Volume 26, Number 3: E195-273 Mar 2024

<https://journalofethics.ama-assn.org/issue/critical-pedagogies-health-professions-education>

Psychiatric Inpatient Environmental Architecture

Inpatient psychiatric units designed to reduce patients' risk of harm to self or others can compromise patients' comfort. Some environmental modifications prioritize safety by limiting patients' access to personal items. This set of clinical phenomena is not ethically neutral and should prompt us to carefully consider when and how patients' experiences of their care environments

undermine therapeutic goals of their hospitalizations. This theme issue investigates which criteria we should use to assess and evaluate patients' risk of harm to self or others and which values we should rely upon to guide which iatrogenic harm risks we accept as products or byproducts of clinical and organizational environmental designs.

[New issue; No digest content identified]

American Journal of Human Genetics

Feb 01, 2024 Volume 111 Issue 2p211-402

<https://www.cell.com/ajhg/current>

This Month in The Journal

Alyson B. Barnes, Kylee L. Spencer, Sara B. Cullinan

Human genetic variation influences susceptibility to infectious disease. Antibodies, stable biological markers of the response to infection, can be measured and leveraged to understand disease exposure, chronic infection state, and risk. Measured antibody titers in combination with genome-wide genotyping data can be used to identify common variants that influence both susceptibility and response to infectious disease. In this issue, Chong et al. perform a genome-wide association study of quantitative antibody responses to 45 antigens on the 9,611 individuals in the UK Biobank with both serology and imputed genetic data.

American Journal of Infection Control

March 2024 Volume 52 Issue 3 p261-380

<http://www.ajicjournal.org/current>

Major Articles

COVID-19 testing and vaccination uptake among youth and young adults: Disparities by age, race/ethnicity, sexual orientation, and gender identity

Jiayi Xu, Shreya S. Narla, Shahin Davoudpour, Megan M. Ruprecht, Michael G. Curtis, Gregory Phillips II

Published online: September 21, 2023

p312-319

State of the Science Reviews

Pre-extensively drug-resistant and extensively drug-resistant tuberculosis in Latin America and the Caribbean: A systematic review and meta-analysis

Esteban A. Alarcon-Braga, et al.

Published online: December 05, 2023

p349-357

American Journal of Preventive Medicine

March 2024 Volume 66 Issue 3 p389-572

<https://www.ajpmonline.org/current>

[New issue; No digest content identified]

American Journal of Public Health

March 2024 114(3)

<http://ajph.aphapublications.org/toc/ajph/current>

[New issue; No digest content identified]

American Journal of Tropical Medicine and Hygiene

Volume 110 (2024): Issue 2 (Feb 2024)

<https://www.ajtmh.org/view/journals/tpmd/110/2/tpmd.110.issue-2.xml>

[Reviewed earlier]

Annals of Internal Medicine

January 2024 Volume 177, Issue 1

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 327 February 2024

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/327/suppl/C>

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

<http://resource-allocation.biomedcentral.com/>

(Accessed 02 Mar 2024)

[No new digest content identified]

BMC Health Services Research

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 02 Mar 2024)

[Individual and social determinants of COVID-19 vaccine hesitancy and uptake in Northwest Syria](#)

The COVID-19 outbreak devastated the fragmented health system in Syria, a war-torn country, and exaggerated the demands for humanitarian assistance. COVID-19 vaccination was rolled out in Northwest Syria, an a...

Authors: Orwa Al-Abdulla, Maher Alaref, Agneta Kallström and Jussi Kauhanen

Citation: BMC Health Services Research 2024 24:265

Content type: Research Published on: 1 March 2024

BMC Infectious Diseases

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 02 Mar 2024)

[No new digest content identified]

BMC Medical Ethics

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 02 Mar 2024)

[No new digest content identified]

BMC Medicine

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 02 Mar 2024)

[No new digest content identified]

BMC Pregnancy and Childbirth

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 02 Mar 2024)

[No new digest content identified]

BMC Public Health

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 02 Mar 2024)

[Risk perception and trust in the relationship between knowledge and HPV vaccine hesitancy among female university students in China: a cross-sectional study](#)

Cervical cancer poses a heavy health burden in China, with the second highest incidence and mortality rate among female tumors, yet human papillomavirus (HPV) vaccination rate among female university students ...

Authors: Xing Chen, Lei Wang, Yan Huang and Luying Zhang

Citation: BMC Public Health 2024 24:667

Content type: Research Published on: 1 March 2024

[Health system barriers to the first dose of measles immunization in Ethiopia: a qualitative study](#)

Ethiopia has made considerable progress toward measles elimination. Despite ongoing efforts, the country remains among those with the highest number of children missing their initial dose of measles vaccine, a...

Authors: Meron Addis, Wubegzier Mekonnen and Abiy Seifu Estifanos

Citation: BMC Public Health 2024 24:665

Content type: Research Published on: 1 March 2024

[Text analysis of billboards and infographic graphics advertising COVID-19 on promoting preventive behaviors and taking vaccination against the coronavirus pandemic and investigating the opinions of the Iranian adult population](#)

Advertising is one of the most important solutions that health centers and medical services around the world use to try to encourage public opinion to create a positive attitude towards preventive measures and...

Authors: Fereshteh Mohamadpour, Gary Groot, Ardalan Askarian and Mehrdad Askarian

Citation: BMC Public Health 2024 24:651

Content type: Research Published on: 1 March 2024

[Knowledge, risk perception and uptake of COVID-19 vaccination among internally displaced persons in complex humanitarian emergency setting, Northeast Nigeria](#)

Owing to crowded and unsanitary conditions, internally displaced persons (IDPs) have an increased risk of COVID-19 infection. Adoption of COVID-19 preventive measures among this population is premised on accur...

Authors: Saheed Gidado, Melton Musa, Ahmed Ibrahim Ba'aba, Mark Rohit Francis, Lilian Akudo Okeke, Fatima Lawan Bukar, Patrick M. Nguku, Idris Suleman Hadejia, Isa Ali Hassan, Ibrahim Muhammad Bande, Martins Onuoha, Rabi Usman, Gideon Ugbenyo, Ntadom Godwin, Elsie Ilori, Aisha Aliyu Abulfathi...

Citation: BMC Public Health 2024 24:634

Content type: Research Published on: 28 February 2024

BMC Research Notes

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 02 Mar 2024)

[No new digest content identified]

BMJ Evidence-Based Medicine

February 2024 - Volume 29 - 1

<https://ebm.bmj.com/content/29/1>

[Reviewed earlier]

BMJ Global Health

February 2024 - Volume 9 - 2

<https://gh.bmj.com/content/9/2>

[Reviewed earlier]

Bulletin of the Atomic Scientists

January 2024

<https://thebulletin.org/magazine/2024-01/>

[Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(3); 2024 Mar 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/456622/>

Editorials

[Digital health solutions to improve health care: a call for papers](#)

Divya Lakhotia, Rapeepong Suphanchaimat, Walaiporn Patcharanarumol, Alain Labrique, Viroj Tangcharoensathien

Bull World Health Organ. 2024 Mar 1; 102(3): 150–150A. Published online 2024 Mar 1.

doi: 10.2471/BLT.24.291451

PMCID: PMC10898284

[2024 Global Symposium on Health Systems Research](#)

Hirotsugu Aiga, Ikuo Takizawa, Stephanie M Topp, Hitoshi Murakami, Sarah Louise Barber, Yasuhiko Kamiya, Kumanan Rasanathan, Adnan A Hyder

Bull World Health Organ. 2024 Mar 1; 102(3): 151–151A. Published online 2024 Mar 1.

doi: 10.2471/BLT.24.291344

PMCID: PMC10898285

Cell

Feb 29, 2024 Volume 187 Issue 5 p1017-1314

<https://www.cell.com/cell/current>

Leading Edge

[Five decades of genetics and genomics](#)

The Cell Editorial Team

Some of the most significant discoveries in the life sciences over the last 50 years stem from genetics and genomics. This field has also seen large-scale collaborative efforts yield fundamental

milestones and results, such as the Human Genome Project. Despite a long road ahead, progress in both basic and clinical genetics now drives sweeping efforts to cure complex human ailments such as blood and psychiatric disorders, metabolic diseases, cancer, and neurodegeneration. While these large tent-pole endeavors receive the most attention, cutting-edge modern genetics techniques are foundational to the science that happens daily across the biomedical life sciences.

[Past, present, and future of CRISPR genome editing technologies](#)

Martin Pacesa, Oana Pelea, Martin Jinek

A broad survey of the genome editing landscape, highlighting the potential and the challenges of genome editing applications for research and therapeutics.

Child Care, Health and Development

Volume 50, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 115, Issue 3 Pages: 375-626 March 2024

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

Subcutaneous Biologics: Clinical Pharmacology and Drug Development

[Reviewed earlier]

Clinical Therapeutics

February 2024 Volume 46 Issue 2 p85-184

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

Clinical Trials

Volume 21 Issue 1, February 2024

<https://journals.sagepub.com/toc/ctja/21/1>

[Reviewed earlier]

Conflict and Health

<http://www.conflictandhealth.com/>

[Accessed 02 Mar 2024]

[Implementation of lockdown, quarantine, and isolation measures in the context of COVID-19 among internally displaced persons in Burkina Faso: a qualitative study](#)

Authors: Kadidiatou Kadio, Antarou Ly, Adidjata Ouédraogo, Mohamed Ali Ag Ahmed, Sanni Yaya and Marie-Pierre Gagnon

Content type: Research 1 March 2024

Contemporary Clinical Trials

Volume 137 February 2024

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/137/suppl/C>

[Reviewed earlier]

The CRISPR Journal

Volume 7, Issue 1 / February 2024

<https://www.liebertpub.com/toc/crispr/7/1>

[Reviewed earlier]

Current Genetic Medicine Reports

Volume 11, issue 1-2, June 2023

<https://link.springer.com/journal/40142/volumes-and-issues/11-1>

[Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 2 2024

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

Current Opinion in Infectious Diseases

April 2024 - Volume 37 - Issue 2

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[New issue; No digest content identified]

Current Protocols in Human Genetics

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 02 Mar 2024]

[No new digest content identified]

Developing World Bioethics

Volume 24, Issue 1 Pages: 1-48 March 2024

<https://onlinelibrary.wiley.com/toc/14718847/current>

Access to Essential Medicines for Global Health and the Human Right to Health
EDITORIAL

[Morality and Access to Essential Medicines: Pairing the Theoretical and Practical](#)

Michael Da Silva SJD, Andreas Albertsen PhD

Pages: 3-5

First Published: 08 February 2024

SPECIAL ISSUE ARTICLES

[Global Health Impact: Human rights, access to medicines, and measurement](#)

Nicole Hassoun

Pages: 37-48

First Published: 07 February 2024

Development in Practice

Volume 34, Issue 1, 2024

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

Development Policy Review

Volume 42, Issue 2 March 2024

<https://onlinelibrary.wiley.com/toc/14677679/current>

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

Disasters

Volume 48, Issue 1 January 2024

<https://onlinelibrary.wiley.com/toc/14677717/2024/48/1>

[Reviewed earlier]

EMBO Reports

Volume 25 Issue 2 13 February 2024

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 2—February 2024

<http://wwwnc.cdc.gov/eid/>

[New issue; No digest content identified]

Epidemics

Volume 45 December 2023

<https://www.sciencedirect.com/journal/epidemics/vol/45/suppl/C>

[Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 1 Pages: 1-48 January–February 2024

<https://onlinelibrary.wiley.com/toc/25782363/current>

**• Local context and emergency research • Participant fraud in online research
Passing demands in autism research :: Women missing in phase I trials**

[Reviewed earlier]

Ethics & International Affairs

Volume 37 - Issue 4 - Winter 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023)

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C>

[Reviewed earlier]

The European Journal of Public Health

Volume 33, Issue 6, December 2023

<https://academic.oup.com/eurpub/issue/33/6>

[Reviewed earlier]

Expert Review of Vaccines

Vol 23 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

Foreign Affairs

March/April 2024 Volume 103, Number 2

<https://www.foreignaffairs.com/issues/2023/103/2>

[New issue; No digest content identified]

Forum for Development Studies

Volume 51, 2023 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 2 February 2024

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/2>

[Reviewed earlier]

Genome Medicine

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 02 Mar 2024]

[No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024)

<https://www.tandfonline.com/toc/zgha20/current?nav=toclist>

[Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 1 February 28, 2024

<http://www.ghspjournal.org/content/current>

REVIEWS

Open Access

[When a Toolkit Is Not Enough: A Review on What Is Needed to Promote the Use and Uptake of Immunization-Related Resources](#)

Samantha Jaffe, Ankita Meghani, Jessica C. Shearer, Ami Karlage, Megan B. Ivankovich, Lisa R. Hirschhorn, Katherine E.A. Semrau and Erin McCarville

Global Health: Science and Practice February 2024, 12(1):e2300343; <https://doi.org/10.9745/GHSP-D-23-00343>

While resources like toolkits and guidance play an important role in promoting adherence to evidence-based practice in the administration of routine immunization programs, simply creating these resources is not enough. More work is needed to understand how to promote uptake and use of these resources by routine immunization programs.

Global Legal Monitor & Legal Reports – Library of Congress/USA

<https://www.loc.gov/collections/global-legal-monitor/>

https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc

[Accessed 02 Mar 2024]

[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024)

<http://www.tandfonline.com/toc/rqph20/current>

[Reviewed earlier]

Globalization and Health

<http://www.globalizationandhealth.com/>

[Accessed 02 Mar 2024]

[No new digest content identified]

Health and Human Rights

Volume 25, Issue 2, December 2023

<https://www.hhrjournal.org/volume-25-issue-2-december-2023/>

Special Section: Economic Inequality and the Right to Health

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 1 - January 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

Health Policy and Planning

Volume 38, Issue 10, December 2023

<https://academic.oup.com/heapol/issue/38/10>

[Reviewed earlier]

Health Research Policy and Systems

<http://www.health-policy-systems.com/content>

[Accessed 02 Mar 2024]

[No new digest content identified]

Human Gene Therapy

Volume 35, Issue 3-4 / February 2024

<https://www.liebertpub.com/toc/hum/35/3-4>

[Reviewed earlier]

Humanitarian Practice Network

<https://odihpn.org/>

Featured Publications

[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

Immunity

Feb 13, 2024 Volume 57 Issue 2 p193-400

<https://www.cell.com/immunity/current>

[Reviewed earlier]

Infectious Agents and Cancer

<http://www.infectagentscancer.com/>

[Accessed 02 Mar 2024]

[No new digest content identified]

Infectious Diseases of Poverty

<http://www.idpjournal.com/content>

[Accessed 02 Mar 2024]

[No new digest content identified]

International Health

Volume 15, Issue 6, November 2023
<https://academic.oup.com/inthealth/issue/15/6>
[Reviewed earlier]

International Human Rights Law Review

Volume 12 (2023): Issue 2 (Dec 2023)
<https://brill.com/view/journals/hrlr/12/2/hrlr.12.issue-2.xml>
Table of Contents
[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 3 (2024): March 2024
<https://www.ijcmph.com/index.php/ijcmph/issue/view/110>
Original Research Articles

[Association between the RTS,S/AS01 malaria vaccine and under-nutrition in children aged 10 to 59 months in Siaya County, Kenya](#)

Benard O. Ochieng, Shehu Awandu, Simon Kariuki, Alice Kamau, Benard Asuke, Asito Amolo, Dickens O. Aduda, Erick Muok
1074-1082
DOI: [10.18203/2394-6040.ijcmph20240605](https://doi.org/10.18203/2394-6040.ijcmph20240605)

[An evaluation of primary immunization coverage among 12-23 months children in an urban area of western Maharashtra: a community based cross sectional study](#)

Vilas S. Mane, Gajanan M. Jatti, Lagdir L. Gaikwad, S. M. Mulje
1188--1194
DOI: [10.18203/2394-6040.ijcmph20240618](https://doi.org/10.18203/2394-6040.ijcmph20240618)

International Journal of Epidemiology

Volume 52, Issue 6, December 2023
<https://academic.oup.com/ije/issue>
[Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 1 2024
<https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/1>
Table of contents
[New issue; No digest content identified]

JAMA

February 27, 2024, Vol 331, No. 8, Pages 627-716
<https://jamanetwork.com/journals/jama/currentissue>
[New issue; No digest content identified]

JAMA Health Forum

March 2024, Vol 5, No. 3
<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

JAMA Pediatrics

February 2024, Vol 178, No. 2, Pages 104-208

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

JBI Evidence Synthesis

February 2024 - Volume 22 - Issue 2

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Adolescent Health

March 2024 Volume 74 Issue 3 p395-628

<https://www.jahonline.org/current>

[Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 79 (2024)

<https://www.jair.org/index.php/jair>

Contents

[Reviewed earlier]

Journal of Community Health

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024 , Page 1988-1996

<https://www.cmro.in/index.php/jcmro/issue/view/75>

[New issue; No digest content identified]

Journal of Development Economics

Volume 167 March 2024

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/167/suppl/C>

[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics

Volume 18 Issue 5, December 2023

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

Journal of Epidemiology & Community Health

February 2024 - Volume 78 - 2

<https://jech.bmj.com/content/78/2>

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 16, Issue 4 Pages: 415-580 December 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

Journal of Global Ethics

Volume 19, Issue 3 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 1, February 2024

<https://muse.jhu.edu/issue/52063>

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 _ Issue 1

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

Journal of Infectious Diseases

Volume 228, Issue 12, 15 December 2023

<https://academic.oup.com/jid/issue/228/12>

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 1 Pages: 1-772 January 2024

<https://onlinelibrary.wiley.com/toc/10991328/current>

[Reviewed earlier]

Journal of Medical Ethics

March 2024 - Volume 50 - 3

<http://jme.bmj.com/content/current>

Feature article

[The revised International Code of Medical Ethics: an exercise in international professional ethical self-regulation](#)

Free

Ramin W Parsa-Parsi¹, Raanan Gillon², Urban Wiesing³

Correspondence to Dr Ramin W Parsa-Parsi, Department for International Affairs, German Medical Association, Berlin 10623, Germany; rparsa@baek.de

Abstract

The World Medical Association (WMA), the global representation of the medical profession, first adopted the International Code of Medical Ethics (ICoME) in 1949 to outline the professional duties of physicians to patients, other physicians and health professionals, themselves and society as a whole. The ICoME recently underwent a major 4-year revision process, culminating in its unanimous adoption by the WMA General Assembly in October 2022 in Berlin. This article describes and discusses the ICoME, its revision process, the controversial and uncontroversial issues, and the broad consensus achieved among WMA constituent members, representing over 10 million physicians worldwide. The authors analyse the ICoME, including its response to contemporary changes and challenges like ethical plurality and globalisation, in light of ethical theories and approaches, reaching the conclusion that the document is a good example of international ethical professional self-regulation.

Journal of Patient-Centered Research and Reviews

Volume 10, Issue 4 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

The Journal of Pediatrics

Volume 266 March 2024

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/266/suppl/C>

[New issue; No digest content identified]

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) Issue 1

<https://www.tandfonline.com/toc/jppp20/17/1>

[Reviewed earlier]

Journal of Public Health Management & Practice

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

Journal of Public Health Policy

Volume 44, issue 4, December 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-4>

[Reviewed earlier]

Journal of the Royal Society – Interface

February 2024 Volume 21 Issue 211

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 1, January 2024

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

Journal of Virology

Volume 98 • Number 2 • February 2024

<http://jvi.asm.org/content/current>

[New issue; No digest content identified]

The Lancet

Mar 02, 2024 Volume 403 Number 10429 p781-876, e9-e20

<https://www.thelancet.com/journals/lancet/issue/current>

Editorial

The Pandemic Treaty: shameful and unjust

The Lancet

The Intergovernmental Negotiating Body (INB), which is tasked under WHO with drawing up an international instrument on pandemic prevention, preparedness, and response, will sit for the 9th and final time from March 18–29. In the 2 years since it first met, hundreds of hours and unknown costs have been spent, but the political impetus has died. The convention is now at a critical juncture: the final text for countries to ratify is due to be presented at the World Health Assembly in May. With only limited days of negotiation left and a long way to go to secure a meaningful agreement, it is now or never for a treaty that can make the world a safer place.

It is hard to remember sometimes, among the highly diplomatic and technical negotiations, but that is what this treaty is trying to do: to protect all people, in all countries, no matter how rich or poor, from harm. As The Lancet went to press, a new publicly available draft text was awaited, but judging from the most recently available version, from October, 2023, the treaty will fail in this aim. Much of the language is greatly weakened from the initial ambition, filled with platitudes, caveats, and the term “where appropriate”. A key recommendation from the Independent Panel for Pandemic Preparedness and Response, met with widespread support, was the need for a treaty that would “address gaps in international response, clarify responsibilities between States and international organisations, and establish and reinforce legal obligations and norms”. At the heart of this recommendation was the need to ensure that high-income countries and private companies behave fairly, that they do not stockpile millions of excess doses of vaccine or refuse to share life-saving knowledge and products, and that there are mechanisms to ensure that countries work together rather than against each other. These issues still represent the broad sticking points in current negotiations: access and benefit sharing (who gets what, how much, and when) and governance and accountability (to what degree are countries made to do something).

The word equity appears nine times in the October negotiating text, including as a guiding principle of the whole treaty. But in reality, Article 12 stipulates that WHO would have access to only 20% of

“pandemic-related products for distribution based on public health risks and needs”. The other 80%—whether vaccines, treatments, or diagnostics—would be prey to the international scramble seen in COVID-19 that saw vital health technologies sold to the highest bidder. Most of the world's peoples live in countries that might not be able to afford these products, but 20% seems to be all that high-income countries were willing to agree to. This is not only shameful, unjust, and inequitable, it is also ignorant. Creating and signing up to a strong and truly equitable set of terms on access and benefit sharing is not an act of kindness or charity. It is an act of science, an act of security, and an act of self-interest. There is still time to correct this misjudgment.

Even the anaemic commitments of the agreement are in jeopardy. Independent monitoring of whether countries are complying with their commitments is essential for the efficacy and longevity of the treaty. Yet, as the likes of Nina Schwalbe and colleagues have pointed out, all indications suggest that the governance and accountability mechanisms of the treaty are being further undermined. There is little in the way of clear enforceable obligations to prevent zoonotic disease outbreaks, implement One Health principles, strengthen health systems, or counter disinformation. Heads of states and the INB might not see pandemic governance as a priority now, but it is fundamental to the success of any agreement.

Creating a global convention acceptable to all is undoubtedly a challenge. The aims for a pandemic treaty are easy to articulate but many are difficult to enact and agree to. The INB might be doing its best, but ultimately it is the politicians of G7 countries who must put aside vested industry interests and finally understand that in a pandemic it is not possible to protect only your own citizens: the health of one depends on the health of all. Millions of lives that could have been saved during the COVID-19 pandemic were not. Far from making amends, a handful of powerful countries are sabotaging the best chance to translate the lessons from the COVID-19 pandemic into legally binding commitments that will protect us all. The treaty is an opportunity that must not be squandered.

Comment

[Hecolin vaccine: long-term efficacy against HEV for a three-dose regimen](#)

Florence Abravanel, Sébastien Lhomme

Articles

[Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial](#)

Shoujie Huang, et al.

The Lancet Child & Adolescent Health

Mar 2024 Volume 8 Number 3 p175-244, e2-e5

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

Lancet Digital Health

Mar 2024 Volume 6 Number 3 e145-e229

<https://www.thelancet.com/journals/landig/issue/current>

Articles

[Optimal strategies to improve uptake of and adherence to HIV prevention among young people at risk for HIV acquisition in the USA \(ATN 149\): a randomised, controlled, factorial trial](#)

Dallas Swendeman, et al. on behalf of the Adolescent HIV Medicine Trials Network (ATN) CARES Study Team

Review

[Characterisation of digital therapeutic clinical trials: a systematic review with natural language processing](#)

Brenda Y Miao, et al.

Lancet Global Health

Mar 2024 Volume 12 Number 3 e341-e529

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

Lancet Infectious Diseases

Mar 2024 Volume 24 Number 3 p217-328, e137-e206

<https://www.thelancet.com/journals/laninf/issue/current>

Articles

[Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic](#)

Luis Rivera Mejía, et al.

Open Access

Personal View

[Overcoming publication and dissemination bias in infectious diseases clinical trials](#)

Martin P Grobusch, et al.

Lancet Public Health

Mar 2024 Volume 9 Number 3 e147-e206

<https://www.thelancet.com/journals/lanpub/issue/current>

[New issue; No digest content identified]

Lancet Respiratory Medicine

Mar 2024 Volume 12 Number 3 p181-254, e7-e12

<https://www.thelancet.com/journals/lanres/issue/current>

Articles

[The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia](#)

Martí Català, et al.

Maternal and Child Health Journal

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 2, February 2024
<http://mdm.sagepub.com/content/current>
[Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue 4 Pages: 999-1374 December 2023
<https://onlinelibrary.wiley.com/toc/14680009/current>
[Reviewed earlier]

Molecular Therapy

Feb 07, 2024 Volume 32 Issue 2 p261-562
<https://www.cell.com/molecular-therapy/current>
[Reviewed earlier]

Nature

Volume 626 Issue 8001, 29 February 2024
<https://www.nature.com/nature/volumes/626/issues/8001>
Editorial 26 Feb 2024

[Why it would be a dangerous folly to end US–China science pact](#)

With renewal of the two countries' decades-long science pact still on hold, there is too much talk about the risks of collaboration — and too little about the benefits.

Nature Biotechnology

Volume 42 Issue 2, February 2024
<https://www.nature.com/nbt/volumes/42/issues/2>
[Reviewed earlier]

Nature Communications

<https://www.nature.com/subjects/health-sciences/ncomms>
(Accessed 02 Mar 2024)
[No new digest content identified]

Nature Genetics

Volume 56 Issue 2, February 2024
<https://www.nature.com/ng/volumes/56/issues/2>
[Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 2, February 2024
<https://www.nature.com/nathumbehav/volumes/8/issues/2>
Article Open Access 04 Dec 2023

[COVID-19 vaccination coverage for half a million non-EU migrants and refugees in England](#)

The authors linked data from non-European Union migrants and resettled refugees to the national COVID-19 vaccination dataset in England, demonstrating disparities in vaccination timing and coverage.

Rachel Burns, Sacha Wyke, Robert W. Aldridge

Nature Medicine

Volume 30 Issue 2, February 2024

<https://www.nature.com/nm/volumes/30/issues/2>

[Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 2, February 2024

<https://www.nature.com/nrd/volumes/23/issues/2>

[Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 3, March 2024

<https://www.nature.com/nrg/volumes/25/issues/3>

[New issue; No digest content identified]

Nature Reviews Immunology

Volume 24 Issue 2, February 2024

<https://www.nature.com/nri/volumes/24/issues/2>

[Reviewed earlier]

New England Journal of Medicine

February 29, 2024 Vol. 390 No. 9

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

njp Vaccines

<https://www.nature.com/npjvaccines/>

[Accessed 02 Mar 2024]

[No new digest content identified]

Pediatrics

Volume 153, Issue 3 March 2024

<https://publications.aap.org/pediatrics/issue/153/3>

[**Fall 2023 ACIP Update on Meningococcal, RSV, COVID-19, and Other Pediatric Vaccines**](#)

Alexandra B. Yonts, MD; Claudia Gaviria-Agudelo, MD, MS; David W. Kimberlin, MD; Sean T. O'Leary, MD, MPH; Grant C. Paulsen, MD

[**Maternal COVID-19 Vaccination and Prevention of Symptomatic Infection in Infants**](#)

Cristina V. Cardemil, MD, MPH; Yi Cao, PhD; Christine M. Posavad, PhD; Martina L. Badell, MD; Katherine Bunge, MD ...

Clinical Report

[Strategies for Improving Vaccine Communication and Uptake](#)

Sean T. O’Leary, MD, MPH, FAAP; Douglas J. Opel, MD, MPH; Jessica R. Cataldi, MD, FAAP; Jesse M. Hackell, MD, FAAP; COMMITTEE ON INFECTIOUS DISEASES ...

PharmacoEconomics

Volume 42, Issue 2 February 2024

<https://link.springer.com/journal/40273/volumes-and-issues/42-2>

[Reviewed earlier]

PLoS Biology

<https://journals.plos.org/plosbiology/>

(Accessed 02 Mar 2024)

[No new digest content identified]

PLoS Genetics

<https://journals.plos.org/plosgenetics/>

(Accessed 02 Mar 2024)

[No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60

(Accessed 02 Mar 2024)

[Geospatial and multilevel clustering of zero-dose children in Kikwit, Democratic Republic of the Congo in 2022](#)

Armand Malembe Mutwadi, Joule Ntwan Madinga, Veerle Vanlerberghe, Placide K. Mbala, Marianne A. B. van der Sande

Research Article | published 29 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002617>

Abstract

Zero-dose children remain highly vulnerable to vaccine-preventable diseases and can sustain transmission even in highly vaccinated populations. The WHO Immunization Agenda 2030 has prioritised reaching out to these children. We assessed the spatial distribution of zero-dose children together with the associated risk factors in a provincial capital in the Democratic Republic of Congo. A cross sectional survey was conducted in the city of Kikwit between September 28 and October 14, 2022. Data were collected both at household and health area level. QGIS and SATscan were used to describe and identify hotspots among zero-dose children, and a mixed effect logistic regression model was used to identify risk factors. Overall, 1,863 children aged 12–23 months were enrolled. Kikwit city had a 16.3% zero-dose prevalence, with significant variation between and within health zones. Two hotspots were identified through geospatial analysis, each spanning multiple health areas. Multilevel analysis revealed significant clustering at health area level and found six associated risk factors. These include the absence of home visits by community health workers (aOR = 1.90), living more than a kilometre from a health centre (aOR = 1.95), the mother’s lack of tetanus vaccination (aOR = 3.16), and inability to name a vaccine-preventable disease (aOR = 3.20). However, secondary (aOR = 0.56) or tertiary (aOR = 0.21) education of mothers/guardians and belonging to Bunda (aOR = 0.36) or Mbala (aOR = 0.52) ethnicity reduced the risk of zero-dose. We observed a high prevalence of zero-dose children with a heterogeneous spatial distribution of

epidemiological importance. Due to sub-zonal diversity, a health zone approach to reduce zero-dose immunization appears very limited. Zero-dose prevalence was related to the community health workers' home visit, to the distance of residence to a health centre and to household-level factors. Geospatial results could help in targeting priority health areas and communities for vaccination.

[Parental vaccine hesitancy and acceptance of a COVID-19 vaccine: An internet-based survey in the US and five Asian countries](#)

Grace Joachim, Shu-Fang Shih, Awnish Singh, Yogambigai Rajamoorthy, Harapan Harapan, Hao-Yuan Chang, Yihan Lu, Abram L. Wagner

Research Article | published 28 Feb 2024 PLOS Global Public Health

<https://doi.org/10.1371/journal.pgph.0002961>

PLoS Medicine

<http://www.plosmedicine.org/>

(Accessed 02 Mar 2024)

[No new digest content identified]

PLoS Neglected Tropical Diseases

<http://www.plosntds.org/>

(Accessed 02 Mar 2024)

[No new digest content identified]

PLoS One

<http://www.plosone.org/>

[Accessed 02 Mar 2024]

[No new digest content identified]

PLoS Pathogens

<http://journals.plos.org/plospathogens/>

[Accessed 02 Mar 2024]

[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

February 27, 2024 vol. 121 no. 9

<https://www.pnas.org/toc/pnas/121/9>

[New issue; No digest content identified]

PNAS Nexus

Volume 3, Issue 2, February 2024

<https://academic.oup.com/pnasnexus/issue/3/2>

Editorial

[Envisioning the future of the AI research ecosystem](#)

Sethuraman Panchanathan

PNAS Nexus, Volume 3, Issue 2, February 2024, pgae021,

<https://doi.org/10.1093/pnasnexus/pgae021>

Extract

The time to think critically about how we responsibly and equitably develop and deploy AI is now. Artificial intelligence is set to transform innovation, science, and society. The complexity of AI lies in integrating data, software, models, and, most importantly, human knowledge and talent. The responsibility lies with all of us to safely integrate AI systems into society and the research ecosystem. As director of the U.S. National Science Foundation, I am acutely aware of the pivotal role our agency plays in fostering AI research and development that accelerates scientific discovery, adheres to ethical and equitable best practices, and upholds our democratic values. We envision that the future AI research ecosystem will be defined by several characteristics: democratized access to computational power, data, sophisticated software, and models across academia, industry, and small businesses; interdisciplinary collaboration across the humanities, physical sciences, social sciences, and engineering disciplines; and global governance frameworks setting standards for international collaboration.

Prehospital & Disaster Medicine

Volume 39 - Issue 1 - February 2024

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

Preventive Medicine

Volume 180 March 2024

<https://www.sciencedirect.com/journal/preventive-medicine/vol/180/suppl/C>

[Reviewed earlier]

Proceedings of the Royal Society B

14 February 2024 Volume 291 Issue 2016

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

Public Health

Volume 227 Pages e1-e4, 1-298 (February 2024)

<https://www.sciencedirect.com/journal/public-health/vol/227/suppl/C>

[Reviewed earlier]

Public Health Ethics

Volume 16, Issue 3, November 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

Public Health Genomics

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

Public Health Reports

Volume 139 Issue 1, January/February 2024

<https://journals.sagepub.com/toc/phrg/139/1>

[Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 4, March 2024

<https://journals.sagepub.com/toc/QHR/current>

[New issue; No digest content identified]

Research Ethics

Volume 20 Issue 1, January 2024

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

Reproductive Health

<http://www.reproductive-health-journal.com/content>

[Accessed 02 Mar 2024]

[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

<https://www.paho.org/journal/en>

[No new digest content identified]

Risk Analysis

Volume 44, Issue 3 Pages: 509-737 March 2024

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

Risk Management and Healthcare Policy

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 02 Mar 2024]

[Reviewed earlier]

Science

Volume 383| Issue 6686| 1 Mar 2024

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 1 February 2024

<https://link.springer.com/journal/11948/volumes-and-issues/30-1>

[Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 736| 28 Feb 2024

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

Scientific Reports

<https://www.nature.com/srep/articles?type=article>

[Accessed 02 Mar 2024]

[No new digest content identified]

Social Science & Medicine

Volume 343 February 2024

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/343/suppl/C>

[New issue; No digest content identified]

Systematic Reviews

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 02 Mar 2024]

[No new digest content identified]

Theoretical Medicine and Bioethics

Volume 44, Issue 6 December 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-6>

[Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 57 January–February 2024

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/57/suppl/C>

[Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 2 Pages: i-iv, 73-160 February 2024

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

Vaccine

Volume 42, Issue 6 Pages 1195-1406 (27 February 2024)

<https://www.sciencedirect.com/journal/vaccine/vol/42/issue/6>

Review article Open access

[Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review](#)

Rose Slavkovsky, Emily Callen, Clint Pecenka, Mercy Mvundura

Pages 1200-1210

This [systematic review](#) aims to summarize the available evidence on the cost of [HPV vaccine](#) delivery in low- and middle-income countries (LMICs). This updated evidence is eminent given

recent global efforts to revitalize HPV vaccine delivery following the COVID-19 pandemic and can be used to inform planning for program sustainability...Our systematic review evidence suggests that HPV vaccine delivery costs vary widely depending on country and stage of implementation when costing was done. Areas for further research include costing when programs are beyond the introduction phase and in LMICs outside of Africa.

Research article Abstract only

[A review of potential use cases for measles-rubella, measles-mumps-rubella, and typhoid-conjugate vaccines presented on microarray patches](#)

Adam Soble, Melissa Ko, Shawn Gilchrist, Stefano Malvolti, ... Tiziana Scarna

Pages 1230-1246

Vaccines

<https://www.mdpi.com/journal/vaccines>

[Accessed 02 Mar 2024]

Latest Articles [Selected]

Open Access Systematic Review

[Barriers to and Facilitators for Accessing HPV Vaccination in Migrant and Refugee Populations: A Systematic Review](#)

by Davide Graci, et al.

Vaccines 2024, 12(3), 256; <https://doi.org/10.3390/vaccines12030256> - 29 Feb 2024

Abstract

Human papillomavirus (HPV) is the most prevalent sexually transmitted virus globally and a primary cause of cervical cancer, which ranks fourth among tumors in both incidence and mortality. Despite the availability of effective vaccines worldwide, HPV vaccination rates vary, especially among migrant and refugee populations. Indeed, migrant status may act as a determinant against accessing vaccinations, among many other factors. The objective of this paper is to evaluate barriers to and facilitators for accessing HPV vaccination in migrant and refugee populations. A systematic review of the existing peer-reviewed academic literature was conducted according to the PRISMA 2020 guidelines in which we examined thirty-four studies to evaluate HPV vaccination rates in these populations and identify factors acting as barriers or facilitators. Key determinants include socio-economic status and health literacy. Communication barriers, including language and cultural factors, also impact access to information and trust in the health workforce. Understanding and considering these factors is crucial for developing proper and inclusive vaccination strategies to ensure that no population is overlooked.

Value in Health

March 2024 Volume 27 Issue 3 p271-382

<https://www.valueinhealthjournal.com/current>

[New issue; No digest content identified]

World Development

Volume 175 March 2024

<https://www.sciencedirect.com/journal/world-development/vol/175/suppl/C>

[Reviewed earlier]

.....

.....

Contents [click to move among sections]

[:: Milestones, Perspectives](#)

[:: WHO](#)

[:: Organization Announcements](#)

[:: Journal Watch](#)

[:: Pre-Print Servers](#)

.....

.....

Pre-Print Servers

Gates Open Research

<https://gatesopenresearch.org/browse/articles>

[Accessed 02 Mar 2024]

Selected Research

Research Article metrics AWAITING PEER REVIEW

[**Developing a framework for understanding policy decision-making behaviors in the transition of a HIV prevention program towards sustainability: a case study from Zambia's voluntary medical male circumcision program**](#)

[version 1; peer review: awaiting peer review]

Nishan Gantayat, James Baer, Alok Gangaramany, Steve Kretschmer, Rasi Surana, Alick Samona, Njekwa Mukambe, Bright Jere, Tina Chinsenga, Ram Prasad, Stephen Goetschius, Saransh Sharma
Peer Reviewers Invited

Funder

Bill and Melinda Gates Foundation

PUBLISHED 01 Mar 2024

medRxiv

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 02 Mar 2024]

[Filter: All articles]

[**Ineffectiveness of international travel restrictions to contain spread of the SARS-CoV-2 Omicron BA.1 variant: a continent-wide laboratory-based observational study from Africa**](#)

Carlo Fischer, et al.

medRxiv 2024.02.27.24303356; doi: <https://doi.org/10.1101/2024.02.27.24303356>

... Unilateral travel bans were poorly effective because by the time they came into effect, BA.1 was already widespread in Africa and beyond. PCR-based variant typing combined with mobility-based mathematical modelling can inform rapidly and cost-efficiently on Rt, spread to inform non-pharmaceutical interventions.

[**A Systematic Review on Malaria and Tuberculosis \(TB\) Vaccine Challenges in Sub-Saharan African Clinical Trials**](#)

Maonezi Abas Hamisi, Nur Ain Mohd Asri, Aini Syahida Mat Yassim, Rapeah Suppian

medRxiv 2024.02.28.24302787; doi: <https://doi.org/10.1101/2024.02.28.24302787>

[**Evaluating the Risk of Conflict on Recent Ebola Outbreaks in Guinea and the Democratic Republic of the Congo**](#)

Gina E C Charnley, Nathan Green, Ilan Kelman, Espoir B Malembaka, Katy A M Gaythorpe

medRxiv 2023.05.30.23290713; doi: <https://doi.org/10.1101/2023.05.30.23290713> Revision

THE SPREAD OF INFECTIOUS DISEASES IN MIGRATION ROUTES BETWEEN CARAVANS AND RESIDENT COMMUNITIES: MODELLING YELLOW FEVER IN CENTRAL AMERICA

Sabrina Soares Simon, Marcos Amaku, Eduardo Massad

medRxiv 2024.02.27.24303456; doi: <https://doi.org/10.1101/2024.02.27.24303456>

OSF Pre-prints

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]

[No new digest content identified]

Wellcome Open Research

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 02 Mar 2024]

Selected Research

Research Article Open Access

[Migration policies versus public health – the ethics of Covid-19 related movement restrictions for asylum seekers in reception centers in Greece in 2020](#)

[version 1; peer review: awaiting peer review]

George Makris

Abstract

Background

The emergency context of the Covid-19 pandemic necessitated the use of national and international public health measures of unprecedented scale to minimize mortality and morbidity, often in conflict with other principles and rights, such as the autonomy of individuals. Concerns have been voiced that for populations facing precarity, such as migrants, a disproportionate and unfair application of restrictive measures, deficient application of protective measures, and even enforcement of restrictive migration policies under the pretext of the pandemic has occurred.

* * * *

Think Tanks

Brookings [to 02 Mar 2024]

<http://www.brookings.edu/>

Research

No new digest content identified.

Center for Global Development [to 02 Mar 2024]

<https://www.cgdev.org/>

All Research [Selected]

No new digest content identified.

Chatham House [to 02 Mar 2024]

<https://www.chathamhouse.org/>

Selected Analysis, Comment, Events
No new digest content identified.

Council on Foreign Relations [to 02 Mar 2024]

<https://www.cfr.org/media/news-releases>

New Releases [Selected]

No new digest content identified.

CSIS [to 02 Mar 2024]

<https://www.csis.org/>

Reports [Selected]

No new digest content identified.

Kaiser Family Foundation [to 02 Mar 2024]

https://www.kff.org/search/?post_type=press-release

Newsroom

[Since Dobbs, Few Large Firms Have Changed Their Plan's Abortion Coverage Policy](#)

February 29, 2024 News Release

According to an analysis of responses to KFF's Employer Health Benefits Survey in 2023, relatively few (8%) large firms (with 200 or more workers) offering health benefits report reducing or expanding coverage for abortion since the U.S. Supreme Court overturned Roe v. Wade with the Dobbs v. Jackson ruling. Since...

[A Third of the Public View Racism as a Major Problem in Health Care; Larger Shares See Racism as a Major Problem in Politics, Criminal Justice, and Other Areas](#)

February 26, 2024 News Release

About a third (32%) of the public view racism as a major problem in health care, fewer than say the same about politics (56%), the criminal justice system (54%), and policing (51%), a new KFF report on the public's views of racism finds. The lower levels of perceived racism in...

McKinsey Global Institute [to 02 Mar 2024]

<https://www.mckinsey.com/mgi/overview>

Latest Research

No new digest content identified.

ODI [Overseas Development Institute] [to 02 Mar 2024]

<https://odi.org/en/publications/>

Publications [Selected]

No new digest content identified.

Pew Research Center [to 02 Mar 2024]

<https://www.pewresearch.org/>

Latest Publications [Selected]

short reads | Feb 28, 2024

[Who likes authoritarianism, and how do they want to change their government?](#)

The share of the public that supports authoritarian systems ranges from 85% in India to 8% in Sweden.

Rand [to 02 Mar 2024]

<https://www.rand.org/pubs.html>

Published Research [Selected]

No new digest content identified.

Urban Institute [to 02 Mar 2024]

<https://www.urban.org/publications>

[New Research Publications - Selected](#)

Research Report

[Examining Afghan Evacuees' Resettlement: Insights and Lessons for Future Humanitarian Populations](#)

March 1, 2024

World Economic Forum [to 02 Mar 2024]

<https://agenda.weforum.org/press/>

Media [Selected]

No new digest content identified.

.....

.....

Public Consultations/Call for Inputs/Call for Papers

[Public consultation of the Global Ethics Charter for the Protection of Healthy Volunteers in Clinical Trials](#)

Inserm Issued 26 Feb 2024 **Comments due by March 30, 2024.**

The « Global Ethics Charter for the Protection of Healthy Volunteers in Clinical Trials » is a key deliverable of the VolREthics initiative that was set up to promote ethical guidelines to protect healthy volunteers in biomedical research. The draft Charter, available in English, French and Spanish is open for public comments up to March 30, 2024.

[Download the draft Charter \(pdf, 201 Ko\)](#)

To submit your or your organization's feedback, [download the public comment document \(docx, 27 Ko\)](#). Please email the completed document to hvworkshop.disc@inserm.fr

[Key Information and Facilitating Understanding in Informed Consent; Draft Guidance for Sponsors, Investigators, and Institutional Review Boards](#)

21 CFR Part 50 [Docket No. FDA-2022-D-2997] **Comments due: 04/30/2024**

SUMMARY:

This draft guidance provides recommendations related to two provisions of the revised Federal Policy for the Protection of Human Subjects (the revised Common Rule) by the U.S. Department of Health and Human Services (HHS) and identical provisions in FDA's proposed rule "Protection of Human Subjects and Institutional Review Boards." FDA's proposed rule, if finalized, would harmonize certain sections of FDA's regulations on human subject protections and institutional review boards (IRBs), to the extent practicable and consistent with other statutory provisions, with

the revised Common Rule, in accordance with the 21st Century Cures Act (Cures Act). The guidance addresses the provisions of the revised Common Rule that require informed consent to begin with key information about the research and to present information in a way that facilitates understanding and identical provisions in FDA’s proposed rule.

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *